Sign in

    Schuyler van den Broek

    Research Analyst at Piper Sandler

    Schuyler van den Broek was an Analyst-Equity at Piper Sandler & Co. from 2022 to 2024, specializing in coverage within the firm’s focus sectors, including agriculture, renewables, business services, chemicals, consumer, diversified industrials, energy, financial services, healthcare, and technology. She contributed to research on select companies across these sectors, supporting investment recommendations and sector analysis, though individual company names and performance rankings have not been publicly disclosed. Van den Broek began her career after earning an undergraduate degree from the University of Michigan in 2020, joining Piper Sandler in 2022 and departing in 2024. She holds an undergraduate degree but no public record of FINRA registration or securities licenses is available.

    Schuyler van den Broek's questions to OPTN leadership

    Schuyler van den Broek's questions to OPTN leadership • Q1 2024

    Question

    Asked about the payer landscape post-label expansion, the long-term evolution of net revenue per prescription, and the factors that would drive a sales force expansion.

    Answer

    Executives stated it's too early for broad payer feedback but anecdotes are positive, with the new indication being added to prior authorization forms. Net revenue per prescription is driven by business actions like co-pay programs, not the label itself. A potential sales force expansion will be based on data and ROI from the current launch efforts.

    Ask Fintool Equity Research AI